---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-019654"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-05-25T23:59:59+00:00"
generated_at: "2026-06-14T14:28:23.681118+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Akebia licenses Vafseo to Medice for Europe, Australia; $10M upfront, up to $100M milestones

## Summary
- Medice gets exclusive rights to market Vafseo (vadadustat) for anemia in CKD dialysis patients in EEA, UK, Switzerland, Australia.
- Akebia receives $10M upfront, up to $100M in commercial milestones, and tiered royalties of 10-30% of net sales.
- Akebia retains 70% of net profit from non-dialysis population if it develops that indication; Medice commercializes both.
- Vafseo approved in 33 countries; regulatory opinions expected in Switzerland and Australia later in 2023.

## SEC filing metadata
- accession: 0001628280-23-019654
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-05-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000162828023019654/0001628280-23-019654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000162828023019654/akba-20230524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-019654
- JSON: https://secwatch.observer/filing/0001628280-23-019654.json
- Plain text: https://secwatch.observer/filing/0001628280-23-019654.txt

## Key facts
- Material Agreements
  Akebia Therapeutics, Inc. entered into License Agreement with MEDICE Arzneimittel Pütter GmbH & Co. KG valued at $10 million (effective 2023-05-24).
  - Action: entry
  - Agreement: license
  - Counterparty: MEDICE Arzneimittel Pütter GmbH & Co. KG
  - Value: $10 million
  - Effective: 2023-05-24
  source text: On May 24, 2023 (the “Effective Date”), Akebia Therapeutics, Inc. (the “Company”) and MEDICE Arzneimittel Pütter GmbH & Co. KG (“Medice”) entered into a License Agreement (the “License Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000162828023019654/0001628280-23-019654-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.